SHANGHAI and BEIJING and HONG KONG, Jan. 25, 2021 /PRNewswire/ — Qiming Enterprise Companions (“Qiming”) at the moment introduced the ultimate shut of our RMB Fund VI at RMB 2.852 billion.
Presently, Qiming has $5.9 billion in property beneath administration, concentrating on early-and-growth-stage healthcare and TMT investments. Qiming raised our first RMB fund in 2010. For the previous ten years, Qiming has demonstrated its capacity to ship constant distinguished returns for LPs and has been properly acknowledged by RMB fund buyers.
Since our inception in 2006, Qiming has invested in additional than 380 corporations, amongst which over 40 achieved unicorn standing. We have now exited our investments in over 130 corporations by way of IPO, M&A or different means. Notable exit offers embody Xiaomi, Gan & Lee Prescription drugs, Meituan, Bilibili, RoboRock, TigerMed, Zai Lab, CanSino Biologics Inc., Venus Medtech, APT Medical, and so forth.
“Qiming has backed a whole lot of good entrepreneurs. We’re happy to see that these corporations are dedicated to social good,” stated Duane Kuang, Founding Managing Associate of Qiming Enterprise Companions, “Qiming managed to shut each RMB and USD funds up to now 5 months, displaying that LPs are optimistic about our funding technique to put money into China’s revolutionary and creating science and expertise, even in the course of the difficult world COVID-19 epidemic in addition to going through altering world environments.”
In 2020, Qiming remodeled 70 investments; over 100 of our current portfolio corporations accomplished new financing rounds. As of at the moment, we’ve got had 13 profitable public listings in our portfolio since 2020. Over 60 of our invested corporations contributed to the struggle towards COVID-19 in China and for the worldwide neighborhood.
“Innovation is the important thing for startups to interrupt by way of and grow to be leaders. Prior to now ten years, we’ve got seen a number of Chinese language entrepreneurs beginning their enterprise and striving to grow to be a worldwide chief in innovation,” stated William Hu, Managing Associate of Qiming Enterprise Companions. “The closing of our new funds will allow us to assist extra visionary founders realizing their entrepreneurial goals.”
About Qiming Enterprise Companions
Based in 2006, Qiming Enterprise Companions is a number one China enterprise capital agency with places of work in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Space.
Presently Qiming Enterprise Companions manages 9 US Greenback funds and six RMB funds with $5.9 billion in property beneath administration. Since our institution, we’ve got invested in excellent corporations within the TMT and healthcare industries on the early and progress phases.
Since our debut, we’ve got backed over 380 fast-growing and revolutionary corporations. Over 130 corporations are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Inventory Trade and Shenzhen Inventory Trade, or achieved exit by way of M&A and different means. There are additionally over 40 portfolio corporations which have achieved unicorn standing.
A lot of our portfolio corporations are at the moment’s most influential companies of their respective sectors, together with Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee Prescription drugs (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech amongst many others.
SOURCE Qiming Enterprise Companions